Biotinylated Human CD84, His,Avitag (CD4-H82E5) is expressed from human 293 cells (HEK293). It contains AA Lys 22 - Gly 225 (Accession # Q9UIB8-3).
Predicted N-terminus: Lys 22
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.
The protein has a calculated MW of 26.5 kDa. The protein migrates as 40-50 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human CD84, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Leukocyte differentiation antigen CD84 is also known as SLAM family member 5 (SLAMF5), which belongs to immunoglobulin (Ig) superfamily. CD84 / SLAMF5 contains one Ig-like C2-type (immunoglobulin-like) domain. CD84 plays a role as adhesion receptor functioning by homophilic interactions and by clustering. CD84 / SLAMF5 increases proliferative responses of activated T-cells and SH2D1A/SAP does not seen be required for this process. Homophilic interactions enhance interferon gamma/IFNG secretion in lymphocytes and induce platelet stimulation via a SH2D1A/SAP-dependent pathway.